姓名：陳毅

性別： 男

政治面貌： 中共黨員

學(xué)歷： 博士

學(xué)位：研究生

職稱：副主任醫(yī)師

博、碩導(dǎo)師：碩導(dǎo)

本崗位工作年數(shù)：14年

研究方向：腫瘤介入治療

榮譽(yù)稱號(hào)：

2024年中國介入醫(yī)師手術(shù)大賽第三名，2017年TACE大賽華北區(qū)二等獎(jiǎng)，北區(qū)三等獎(jiǎng)

學(xué)術(shù)任職：

中國抗癌協(xié)會(huì)介入專委會(huì)青年委員；中國醫(yī)療器械管理委員會(huì)委員；山西省介入醫(yī)師協(xié)會(huì)腫瘤學(xué)組副主任委員；山西省抗癌協(xié)會(huì)腫瘤消融專業(yè)委員會(huì)常委；山西省介入醫(yī)師協(xié)會(huì)常委；《中華介入放射學(xué)電子雜志》通訊編委和審稿專家

近五年承擔(dān)科研課題情況：

主持山西省科技廳面上項(xiàng)目，項(xiàng)目名稱:基于影像組肝癌TACE進(jìn)展的免疫特征預(yù)測(cè)研究，項(xiàng)目編號(hào)：202303021211201

山西省博士后基金項(xiàng)目，項(xiàng)目名稱：經(jīng)動(dòng)脈介入靶向灌注放射性黑色素納米材料治療肝癌的療效及機(jī)制研究，項(xiàng)目編號(hào)：109

完成山西省衛(wèi)健委課題項(xiàng)目，項(xiàng)目名稱：超選擇前列腺動(dòng)脈栓塞治療不能外科手術(shù)切除前列腺增生的臨床療效，項(xiàng)目編號(hào)：2017045

代表性論著及近五年的代表性論文（限10項(xiàng)以內(nèi)）：

1.Colorcoded parametric imaging support display of vessel hemorrhage—an in vitro experiment and clinical validation study. Front. Cardiovasc. Med. 2024,11:1387421（第一作者）

2.Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study. Front Immunol 2024, 15:1449663（通訊作者）

3.Clinical application of interventional embolization in tumor-associated hemorrhage.Ann Transl Med 2020;8(6):394.(第一作者)

4.Nomograms including the controlling nutritional status (CONUT) score in patients with hepatocellular carcinoma undergoing transarterial chemoembolization for prediction survival: A retrospective analysis. British Journal of Nutrition, 2022,128:1966-1974.（第一作者）

5.Using the Controlling Nutritional Status (CONUT) Score for Evaluating Patients with Early-Stage Hepatocellular Carcinoma After Radiofrequency Ablation: A Two-Center Retrospective Study. Cardiovasc Intervent Radiol. 2020 Sep;43(9):1294-1304.(第一作者)

6.Nomogram Based on Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio to Predict Recurrence in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation.Cardiovasc Intervent Radiol. 2021 May 25.(第一作者)

7.Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. Eur Radiol. 2021 May;31(5):3053-3064（共一）

8.Prognostic significance of controlling nutritional status score-based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation. J Gastrointest Oncol 2020;11(5):1024-1039（通訊作者）

9.Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors,International Journal of Hyperthermia, 38:1, 437-446（通訊作者）

10.The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Front. Oncol. 11:783480. doi: 10.3389/fonc.2021.783480(通訊作者)